Exelixis (EXEL) Cash & Current Investments (2010 - 2026)

Exelixis' (EXEL) quarterly Cash & Current Investments came in at $777.2 million in Q2 2026, down 24.64% year-on-year from $1.0 billion in Q2 2025, and down 26.62% quarter-over-quarter from $1.1 billion in Q1 2026.

Exelixis (EXEL) Cash & Current Investments (2010 - 2026) Analysis & Trends

Exelixis' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $777.2 million for Q2 2026.

  • On a quarterly basis, Cash & Current Investments fell 24.64% year-over-year to $777.2 million in Q2 2026; TTM through Apr 2026 was $777.2 million, a 24.64% decrease from a year earlier, with the FY2026 full-year figure at $1.1 billion, down 4.7% from the prior year.
  • Cash & Current Investments retreated to $777.2 million in Q2 2026 per EXEL's latest filing, from $1.1 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $1.6 billion in Q2 2022 and bottomed at $777.2 million in Q2 2026.
  • The 5-year median for Cash & Current Investments is $1.1 billion (2023), against an average of $1.2 billion.
  • Across the five-year window, Cash & Current Investments soared 32.46% in 2022 and slipped 28.68% in 2023, its largest moves.
  • Year by year, Cash & Current Investments stood at $1.3 billion in 2022, then decreased by 23.93% to $995.3 million in 2023, then climbed by 19.48% to $1.2 billion in 2024, then slipped by 16.87% to $988.5 million in 2025, then dropped by 21.38% to $777.2 million in 2026.
  • Per Business Quant, the three latest EXEL Cash & Current Investments figures stand at $777.2 million (Q2 2026), $1.1 billion (Q1 2026), and $988.5 million (Q4 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Oculis Holding AG 66,801.52 Bn 66,801.23 Bn - 283.54 Mn
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn - 61.40 Mn
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 472.27 Bn 467.47 Bn 1.35 Bn 4.79 Bn
5 Vertex Pharmaceuticals 122.18 Bn 114.93 Bn 2.59 Bn 7.25 Bn
6 Regeneron Pharmaceuticals 70.08 Bn 61.32 Bn 3.31 Bn 8.75 Bn
7 Belite Bio 62.34 Bn 62.34 Bn - -
8 Argenx Se 55.86 Bn 50.68 Bn 1.41 Bn 5.18 Bn
9 Alnylam Pharmaceuticals 37.50 Bn 34.49 Bn 959.66 Mn 3.01 Bn
10 Exelixis 14.52 Bn 13.74 Bn 590.86 Mn 777.21 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 777.21 Mn
Jan 2, 2026 1.06 Bn
Oct 3, 2025 988.54 Mn
Jul 4, 2025 791.10 Mn
Apr 4, 2025 1.03 Bn
Jan 3, 2025 1.11 Bn
Sep 27, 2024 1.19 Bn
Jun 28, 2024 1.00 Bn
Mar 29, 2024 963.26 Mn
Dec 29, 2023 995.30 Mn
Sep 29, 2023 1.10 Bn
Jun 30, 2023 1.27 Bn
Mar 31, 2023 1.31 Bn
Dec 30, 2022 1.31 Bn
Sep 30, 2022 1.55 Bn
Jul 1, 2022 1.53 Bn
Apr 1, 2022 1.57 Bn
Dec 31, 2021 1.47 Bn
Oct 1, 2021 1.40 Bn
Jul 2, 2021 1.35 Bn